Skip to main content

Table 1 Demographic and clinical characteristics of study population

From: Total calcium-sensing receptor expression in circulating monocytes is increased in rheumatoid arthritis patients with severe coronary artery calcification

Characteristics RA patients (n = 50) Control subjects (n = 25) P
Age, years 60.9 ± 8.3 59.6 ± 5.3 0.42
Gender (female), % 74.0% 72.0% 0.85
Body mass index, kg/m2 27.0 ± 6.0 28.9 ± 8.3 0.32
Current smokers, % 16.0% 16.0% 1.00
Diabetes, % 6.0% 12.0% 0.36
Family history of cardiovascular disease, % 18.0% 20.0% 0.83
Hypertension, % 64.0% 48.0% 0.50
Current use of antihypertensive therapy, % 44.0% 36.0% 0.50
Systolic blood pressure, mmHg 126.2 ± 17.0 129.3 ± 18.4 0.45
Diastolic blood pressure, mmHg 81.0 ± 12.3 82.6 ± 11.6 0.59
Hypercholesterolemia, % 36.0% 48.0% 0.74
Current use of statins, % 24.0% 16.0% 0.32
Current use of fibrates, % 2.0% 16.0% 0.02
FRS, % 11.4% 13.8% 0.36
RF and/or CCP antibodies, % 86.0% -  
Erosive arthritis, % 54.0% -  
Duration of disease (years) 12.2 ± 8.5 -  
HAQ 0.8 ± 0.7 -  
DAS28-hs-CRP 2.5 ± 0.9 -  
DAS28-hs-CRP ≤3.2, % 80.0% -  
Current methotrexate users, % 90.0% -  
Current anti-TNFα users, % 58.0% -  
Current NSAIDs users, % 30.0% -  
Current corticosteroid users, % 26.0% -  
  1. Values are the mean ± standard deviation (SD) (significant results are indicated in bold). RA, rheumatoid arthritis; FRS, Framingham risk score; RF, rheumatoid factor; CCP, citrullinated cyclic protein; HAQ, health assessment questionnaire; DAS28-hs-CRP, disease activity score 28 high-sensitivity C-reactive protein; TNFα, tumor necrosis factor alpha; NSAIDs, nonsteroidal anti-inflammatory drugs.